Chemotherapy in advanced breast carcinoma. Comparison between doxorubicin-cyclophosphamide and cyclophosphamide-methotrexate-5-fluorouracil-vincristine-prednisone.
作者信息
Parvinen L M, Numminen S
出版信息
Acta Radiol Oncol. 1985 Sep-Oct;24(5):391-4. doi: 10.3109/02841868509134406.
PMID:3002135
Abstract
Two chemotherapeutic regimens were compared in 102 patients with metastatic breast carcinoma, randomized to either doxorubicin-cyclophosphamide (DC) or cyclophosphamide-methotrexate-5-fluorouracil-vincristine-prednisone (CMFVP). The objective response rates were 32 per cent in the former and 35 per cent in the latter group, the complete response rates 6.4 and 21.8 per cent, and mean duration of the remission 7.7 and 11.2 months, respectively. Most responders had multiple metastases and had received previous hormonal treatment. The DC regimen was found to be slightly more toxic than CMFVP.
摘要
相似文献
1
Chemotherapy in advanced breast carcinoma. Comparison between doxorubicin-cyclophosphamide and cyclophosphamide-methotrexate-5-fluorouracil-vincristine-prednisone.
Acta Radiol Oncol. 1985 Sep-Oct;24(5):391-4. doi: 10.3109/02841868509134406.
2
A comparison of intermittent vs. continuous and of adriamycin vs. methotrexate 5-drug chemotherapy for advanced breast cancer. A Cancer and Leukemia Group B study.
Am J Clin Oncol. 1984 Jun;7(3):231-9. doi: 10.1097/00000421-198406000-00007.
3
Adriamycin, dibromodulcitol, and mitomycin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone.阿霉素、二溴卫矛醇和丝裂霉素联合化疗用于先前接受过环磷酰胺、甲氨蝶呤、5-氟尿嘧啶、长春新碱和泼尼松治疗的转移性乳腺癌患者。
Cancer. 1984 May 1;53(9):1841-4. doi: 10.1002/1097-0142(19840501)53:9<1841::aid-cncr2820530907>3.0.co;2-#.
4
A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) in patients with advanced breast cancer.晚期乳腺癌患者中，环磷酰胺、阿霉素和5-氟尿嘧啶（CAF）与环磷酰胺、甲氨蝶呤、5-氟尿嘧啶、长春新碱和泼尼松（CMFVP）的比较。
Breast Cancer Res Treat. 1983;3(2):209-20. doi: 10.1007/BF01803563.
5
Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281.转移性或复发性乳腺癌的联合化疗——一项比较CAF方案、VATH方案以及VATH与CMFVP交替方案的随机III期试验：癌症与白血病B组研究8281
J Clin Oncol. 1995 Jun;13(6):1443-52. doi: 10.1200/JCO.1995.13.6.1443.
6
Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.环磷酰胺、甲氨蝶呤、5-氟尿嘧啶、长春新碱和泼尼松辅助化疗与单药左旋苯丙氨酸氮芥治疗可手术乳腺癌且腋窝淋巴结阳性患者的比较：西南肿瘤协作组20年研究结果
Cancer. 2003 Jan 1;97(1):21-9. doi: 10.1002/cncr.10982.
7
CAP (cyclophosphamide, adriamycin, platinum) vs CMFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisolone) combination chemotherapy in untreated metastatic breast cancer. A preliminary report of a controlled clinical study.环磷酰胺、阿霉素、顺铂（CAP）与环磷酰胺、甲氨蝶呤、5-氟尿嘧啶、长春新碱、泼尼松（CMFVP）联合化疗用于未经治疗的转移性乳腺癌。一项对照临床研究的初步报告。
Cancer Chemother Pharmacol. 1984;13(2):142-4. doi: 10.1007/BF00257133.
8
Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B study.II期乳腺癌术后辅助化疗联合或不交叉至非交叉耐药方案：癌症与白血病B组研究
J Clin Oncol. 1996 May;14(5):1589-98. doi: 10.1200/JCO.1996.14.5.1589.
9
10
Alternating versus sequential therapy in advanced breast cancer.
Medicina (B Aires). 1987;47(3):243-8.
Zotero 插件